Cargando…
Liposomal remdesivir inhalation solution for targeted lung delivery as a novel therapeutic approach for COVID-19
Strong infectivity enables coronavirus disease 2019 (COVID-19) to rage throughout the world. Moreover, the lack of drugs with definite therapeutic effects further aggravates the spread of the pandemic. Remdesivir is one of the most promising anti-severe acute respiratory syndrome coronavirus 2 (SARS...
Autores principales: | Li, Jingjing, Zhang, Kai, Wu, Di, Ren, Lianjie, Chu, Xinyu, Qin, Chao, Han, Xiaopeng, Hang, Taijun, Xu, Yungen, Yang, Lei, Yin, Lifang |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Shenyang Pharmaceutical University
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8529908/ https://www.ncbi.nlm.nih.gov/pubmed/34703490 http://dx.doi.org/10.1016/j.ajps.2021.09.002 |
Ejemplares similares
-
Inhaled Liposomal Antimicrobial Delivery in Lung Infections
por: Bassetti, Matteo, et al.
Publicado: (2020) -
Systemic Protein Delivery via Inhalable Liposomes: Formulation and Pharmacokinetics
por: Ponkshe, Pranav, et al.
Publicado: (2023) -
Pharmacokinetics, safety, and tolerability of inhaled remdesivir in healthy participants
por: Humeniuk, Rita, et al.
Publicado: (2023) -
Mechanisms by Which Liposomes Improve Inhaled Drug Delivery for Alveolar Diseases
por: Ferguson, Laura T., et al.
Publicado: (2023) -
In vivo pharmacokinetic study of remdesivir dry powder for inhalation in hamsters
por: Sahakijpijarn, Sawittree, et al.
Publicado: (2021)